Immtech Receives Approval to Begin Phase II DB289 Trials in Peru for Treatment of PCP.Business Editors & Health/Medical Writers BIOWIRE2K VERNON HILLS, Ill.--(BW HealthWire)--April 24, 2002 Immtech International, Inc., (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : IMMT) announced today that it has received approval from the Government of Peru The government of Peru, as established by the 1993 Constitution, is a presidential representative democratic republic. Legislative branch
phase II of the Company's first drug DB289 for the treatment of Pneumocystis carinii pneumonia Pneumocystis carinii pneumonia (PCP) A lung infection that affects people with weakened immune systems, such as people with AIDS or people taking medicines that weaken the immune system. Mentioned in: AIDS, Antiprotozoal Drugs, Sulfonamides (PCP PCP abbr. 1. phencyclidine 2. primary care physician Pneumocystis carinii pneumonia (PCP) ). The trial will begin in May. DB289 was developed and supported by a National Cooperative Drug Development Grant from the National Institute of Health ("NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. "). Caused by a fungus commonly found in the lungs of immunosuppressed patients (including HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome , transplant, and cancer patients), PCP overgrows the air sacks of the lungs, causing pneumonia that can be life threatening if not treated. DB289 earlier had entered a Phase II site for PCP in South Africa. Peru is a second site that will increase the enrollment of patients in the clinical trials. The trial protocol requires patients to be treated for a total of 21 days. Initial patients will be enrolled in the trial if they are intolerant or cannot be treated with Trimethoprim-Sulfamethoxazole, the standard treatment for PCP. Steve Thompson, the President and CEO of Immtech said, "It is important for us to rapidly enroll new patients in this trial to demonstrate the safety and efficiency of DB289 for treating PCP. The Peruvian site will make a significant impact on the speed with which we will complete this Phase II study." About Immtech International Inc. Immtech International, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of fungal diseases, tuberculosis, hepatitis, pneumonia, diarrhea, and cancer. The Company has rights to a dicationic anti-microbial pharmaceutical platform and is conducting research to develop treatments for commercial use. These dication pharmaceuticals work by blocking life-sustaining enzymes from binding to the minor groove of an organism's DNA, thereby killing the infectious organisms that cause fungal, parasitic, bacterial and viral diseases. For further information, please visit the Company's web site at www.immtech-international.com. "Safe Harbor" Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: Statements in this press release regarding Immtech International, Inc.'s business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-KSB for the most recently ended fiscal year. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion